STOCK TITAN
  1. Home
  2. News
  3. BHC

Bausch Health Companies Inc - BHC STOCK NEWS

Welcome to our dedicated news page for Bausch Health Companies (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch Health Companies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch Health Companies's position in the market.

News
Bausch Health to Announce First-Quarter 2024 Results on May 2
Rhea-AI Summary
Bausch Health Companies Inc. (BHC) will release its first-quarter 2024 financial results on May 2, 2024, followed by a conference call and webcast to discuss the results and provide a business update. Investors can access all materials on the Investor Relations section of the Bausch Health website. The conference call details include the date, time, and webcast link, with a replay available on the investor relations website. Participants can register for the live Q&A session to receive a PIN before the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
earnings
-
News
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals announced that the U.S. Court of Appeals upheld the decision preventing the approval of Norwich Pharmaceuticals' generic version of XIFAXAN until 2029. The Court also invalidated certain patents related to XIFAXAN for treating IBS-D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
fda approval
-
News
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Rhea-AI Summary
Bausch Health Companies Inc. announces the availability of ARAZLO, a topical prescription treatment for acne vulgaris, through BC PharmaCare in Canada. ARAZLO is the only tazarotene lotion approved by Health Canada for acne treatment in patients 10 years and older. The lotion's PRISMATREX technology helps improve patient tolerability, making it a significant addition to Bausch Health's dermatology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
News
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals, Inc. filed a lawsuit against Amneal Pharmaceuticals for seeking approval to market a generic version of XIFAXAN®. The litigation process under the Hatch-Waxman Act has been initiated, triggering a 30-month stay of potential FDA approval for Amneal's ANDA. Bausch Health remains confident in its XIFAXAN® intellectual property and continues to defend it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
none
-
News
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Rhea-AI Summary
Bausch Health, Canada Inc., a part of Bausch Health Companies Inc., announces the first public drug plan listings for UCERIS® aerosol foam to treat distal ulcerative colitis in adults. The treatment is now available in five Canadian provinces, with a focus on expanding access to effective therapies for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
News
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Rhea-AI Summary
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc., released its fourth annual Patient Perspectives IBS Impact Report. The report, in partnership with Fairleigh Dickinson University Poll, surveyed over 850 U.S adults with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). Findings show that a significant portion of patients feel isolated and hide symptoms from loved ones, with many skipping events due to IBS symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
News
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals support a Phase 2 study of RELISTOR in head and neck cancer patients. The study aims to assess the potential of MNTX in treating oral cavity squamous cell carcinoma, led by Dr. Juan P. Cata at MD Anderson Cancer Center. The trial involves preoperative and postoperative MNTX administration with monitoring for two years. Primary and secondary endpoints include drug administration success, tumor characteristics, response rates, and patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
clinical trial
-
News
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Rhea-AI Summary
Bausch Health Companies Inc. (BHC) and Salix Pharmaceuticals release findings from a colonoscopy awareness survey, highlighting patient perspectives on the procedure and preparation process. The survey, conducted in partnership with The Harris Poll, sheds light on barriers to colonoscopy uptake among U.S. residents aged 45+.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News
Bausch Health Companies to Present at Cowen Annual Health Care Conference
Rhea-AI Summary
Bausch Health Companies Inc. (BHC) to participate in Cowen Annual Health Care Conference on March 5, 2024. A fireside chat will be hosted by the management team at 12:50 p.m. EST. Investors can access the live webcast on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
conferences
News
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Rhea-AI Summary
Bausch Health Companies Inc. reports fourth-quarter revenues of $2.41 billion, up 10%, and full-year revenues of $8.76 billion, up 8%. The company shows growth in Salix, International, Solta, and Bausch + Lomb segments. GAAP Net Loss is $39 million for the quarter and $592 million for the year. Adjusted EBITDA is $869 million for the quarter and $3.0 billion for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
earnings
Stock BHC logo
Bausch Health Companies Inc

NYSE:BHC

BHC Rankings

#1478 Ranked by Market Cap
#1934 Ranked by Stock Gains
N/A Ranked by Dividends

BHC Stock Data

3.21B
303.99M
0.91%
79.62%
6.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Laval

About BHC

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###